An evaluation of Ki-67 and PCNA expression in conjunctival and eyelid tumours
The aim of our study was an evaluation of the expression of cell proliferation markers (PCNA and Ki-67) in conjunctival and eyelid papillomas and squamous and basal cell cancers. A series of 9 cases of squamous cell cancer (SCC), 15 cases of basal cell cancer (BCC) and 43 cases of squamous cell papilloma (SCP) were assessed using the immunohistochemical method with monoclonal antibodies. PCNA overexpression was observed in 100% of SCP, in 88.8% of SCC and in 100% of BCC cases. Ki-67 overexpression was seen in 32.5% of cases of SCP, in 22.2% of SCC and in 66.6% of BCC. The results showed that an evaluation of Ki-67 expression is the most valuable cell proliferation marker.
- 1. Barret TL, Smith KJ, Hodge JJ, Butler R, Hall FW, Skelton HG (1997) Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. J Am Acad Dermatol, 37: 430–437.
- 2. Koide N, Koike S, Watanabe H, Yazawa K, Adachi W, Amano J (1999) Basaloid squamous carcinoma of the esophageus with analysis by in situ nick end labeling and PCNA immunostaining. Hepatogastroenterology, 46: 265–271.
- 3. Kręcicki T, Jeleń T, Zalesska-Kręcicka M, Szkudlarek T, Szajowski K (1999) Immunohistochemically stained markers (p53,PCNA,bcl-2) in dysplastic lesions of the larynx. Cancer Lett, 143: 23–28.
- 4. Lu S, Syrjanen K, Havu VK, Syrjanen S (1996) Expression of PCNA is associated with the presence of HPV DNA in skin warts. Arch Dermatol Res, 289: 35–39.
- 5. Rabah R, Sakr W, Thomas R, Lancaster WD, Gregoire L (2000) Human papillomavirus type, Proliferative activity and p53. Arch Pathol Lab Med, 124: 721–724.
- 6. Reszec J, Sulkowska M, Famulski W, Guzinska-Ustymowicz K, Sulkowski S (2002) The expression of tumorigenesis markers in oral papilloma. Pol J Pathol, 53: 195–200.
- 7. Stainbeck RG, Moege J, Heselmeyer KM, Klebe W, Neugebauer W, Borg B, Auer GU (1993) DNA content and PCNA immunoreactivity in oral precancerous and cancerous lesions. Eur J Cancer B Oral Oncol, 29: 279–284.